Daily Cosmetic Research Analysis
Analyzed 64 papers and selected 3 impactful papers.
Summary
Analyzed 64 papers and selected 3 impactful articles.
Selected Articles
1. A Systematic Review on Molecular Toxicology and Omics-Based Risk Assessment of Pigments Used in Dermal Implantation Procedures: Implications for Somatology and Somatic Therapy Practice.
This PRISMA-guided systematic review integrates molecular toxicology and multi-omics evidence on pigments used in dermal implantation procedures, delineating oxidative stress, NF-κB/MAPK-driven inflammation, apoptosis/genotoxicity, type IV hypersensitivity (notably with modern red azo pigments), and dermal-to-lymphatic transport. It contextualizes these mechanisms within evolving regulatory frameworks and translates them into risk-mitigation practices for cosmetic and somatic therapy settings.
Impact: By unifying mechanistic toxicology with omics and regulatory perspectives, this review provides a next-generation framework for evidence-based pigment selection and patient safety in cosmetic tattooing and related procedures.
Clinical Implications: Clinicians and somatic therapists should implement pigment traceability, aseptic technique, PPE, ventilation, and informed consent that addresses pigment migration and delayed reactions; select pigments with established biocompatibility profiles and comply with EU REACH and FDA guidance.
Key Findings
- Mechanistic toxicities include oxidative stress, NF-κB/MAPK-driven inflammation, apoptosis/genotoxicity, and type IV hypersensitivity linked to modern red azo pigments.
- Dermal-to-lymphatic transport of pigment particulates is documented, supporting regional and systemic exposure considerations.
- Transcriptomic and metabolomic data reveal pigment-specific inflammatory and wound-healing gene signatures, enabling mechanism-based biocompatibility profiling.
Methodological Strengths
- PRISMA-guided systematic synthesis across molecular, cellular, and regulatory domains
- Integration of multi-omics (transcriptomics, metabolomics) with mechanistic toxicology for risk assessment
Limitations
- Heterogeneity of included studies and predominance of in vitro/animal evidence limit direct clinical generalizability
- Lack of standardized exposure metrics and limited longitudinal clinical outcome data
Future Directions: Develop standardized pigment exposure assays, real-world registries with longitudinal outcomes, and omics-based safety panels; strengthen post-market surveillance and harmonize regulatory standards.
Pigment implantation (semi-permanent make-up, microblading and cosmetic tattooing) introduces complex pigment mixtures into the dermis, resulting in direct exposure of keratinocytes, fibroblasts and resident immune cells to metals, organic dyes and nanoparticles. Within Somatology and Somatic therapy practice, an allied health discipline concerned with evidence-based care of the skin and body, Somatic Therapists operate at the interface of dermal intervention, molecular exposure and occupational health, underscoring the relevance of mechanistic toxicology for risk-informed professional practice. This PRISMA-guided systematic review synthesises molecular toxicology and omics-based evidence, emphasising oxidative stress generation, inflammatory signalling via NF-κB/MAPK pathways, apoptosis and genotoxicity, T-cell-mediated type IV hypersensitivity reactions associated with modern red azo pigments, and dermal-to-lymphatic transport of particulate matter. Transcriptomic and metabolomic studies consistently demonstrate pigment-specific inflammatory responses and wound-healing gene signatures, supporting mechanism-driven biocompatibility profiling. Regulatory frameworks, including EU REACH Annex XVII Entry 75 and recent FDA guidance on microbial contamination, have strengthened compliance requirements; however, surveillance continues to identify mislabelling, restricted pigments and microbial contamination in some inks. For Somatology and Somatic therapy practice, these findings highlight the importance of evidence-based pigment selection, traceable sourcing, aseptic technique, ventilation, personal protective equipment and informed consent addressing pigment migration and delayed adverse reactions. The integration of molecular outcomes with omics technologies and regulatory oversight provides a next-generation risk assessment framework to advance safe cosmetic practice and public health.
2. Sensitive Skin Improvement Through Bioinformatics-Identified Cosmetic Ingredients That Regulate Transcriptome-Derived Biomarkers.
The authors operationalize a biomarker-driven, mechanism-based approach to sensitive skin by integrating MISSM-derived transcriptomics, bioinformatics-guided ingredient selection, in vitro validation, and a 4-week open-label clinical pilot with longitudinal molecular monitoring. The pipeline identifies inflammatory biomarkers responsive to lactic acid challenge and demonstrates feasibility of minimally invasive transcriptomic surveillance during product use.
Impact: This study pioneers a translational pipeline that links skin transcriptomics to ingredient selection and real-world molecular monitoring, moving cosmeceutical development beyond irritant exclusion toward mechanism-guided personalization.
Clinical Implications: Clinicians and developers can leverage MISSM-based biomarkers to stratify sensitive skin, select mechanism-aligned ingredients, and track molecular response during use, enabling personalized recommendations and objective outcome assessment.
Key Findings
- Established an integrated pipeline combining MISSM transcriptomics, bioinformatics matching, in vitro qRT-PCR validation, and a 4-week open-label clinical pilot.
- Identified sensitive skin-associated inflammatory biomarkers in lactic acid-stimulated keratinocytes and fibroblasts.
- Demonstrated feasibility of minimally invasive, longitudinal molecular monitoring during cosmetic product use.
Methodological Strengths
- Multimodal validation spanning transcriptomics, bioinformatics, cell-based assays, and human pilot testing
- Use of MISSM for minimally invasive, repeated molecular sampling
Limitations
- Open-label pilot without a control group and unspecified sample size limits inference
- Short 4-week duration and heterogeneity of sensitive skin phenotypes
Future Directions: Conduct randomized, controlled, multicenter trials to validate biomarker panels, define responder phenotypes, and link molecular changes to clinical endpoints.
Sensitive skin is characterized by hypersensitivity to normal stimuli, and objective diagnostic tools and treatments are still limited. Currently, cosmetics for sensitive skin are developed through the exclusion of known irritants rather than investigation into the underlying mechanisms of sensitivity. In this study, we developed an integrated pipeline combining transcriptome analysis via microneedle-based skin sampling (MISSM), bioinformatics, in vitro validation, and clinical assessment to identify sensitive skin-associated inflammatory biomarkers and cosmetic ingredients that regulate them. Candidate biomarkers and matched cosmetic ingredients were identified from transcriptomic data and validated in lactic acid-stimulated HaCaT and human dermal fibroblasts via qRT-PCR. A prototype emulsion was developed and evaluated in a 4-week open-label pilot clinical trial with longitudinal molecular monitoring via MISSM. After lactic acid stimulation, sensitive skin-associated biomarkers (
3. A Two-Stage Mohs Micrographic Surgery Technique to Avoid Complex Reconstruction of Large Skin Lesions.
In 51 patients with large non-melanoma skin cancers, a staged/serial Mohs excision strategy enabled primary closure in 90% of cases, with no local recurrences at a mean 31-month follow-up. This technique offers a patient-centered alternative for those refusing flaps/grafts, balancing oncologic control with improved cosmetic outcomes.
Impact: This pragmatic modification of Mohs surgery demonstrates high rates of primary closure without compromising short- to mid-term oncologic outcomes, potentially reducing reconstructive morbidity and improving patient satisfaction.
Clinical Implications: Consider two-stage/serial Mohs excisions for selected large facial or critical-area NMSC patients prioritizing simple closure; discuss trade-offs and plan staged resections to maximize tissue preservation and cosmesis.
Key Findings
- Retrospective cohort of 51 patients with large NMSC treated by serial Mohs excisions (most required two stages).
- Primary closure achieved in 90% of cases, avoiding flaps/grafts.
- No local recurrences observed over a mean 31-month follow-up.
Methodological Strengths
- Real-world cohort with mid-term follow-up
- Clear procedural description enabling reproducibility
Limitations
- Retrospective, single-center design without a control group
- Selection bias (patients refusing reconstruction) and limited external generalizability
Future Directions: Prospective comparative trials assessing cosmesis, quality of life, cost-effectiveness, and long-term oncologic outcomes are warranted.
Mohs Micrographic Surgery (MMS) is considered the most conservative and preserving procedure for removing cutaneous tumors. The major disadvantage of MMS is that tumor involvement in tissue may be underestimated. This may lead to large excisions necessitating complex reconstruction with profound effects on cosmetic results. Some patients refuse complex reconstruction and demand simple closure of post-MMS skin defects. This retrospective cohort study describes our technique of serial Mohs excisions of large non-melanoma skin cancers for patients refusing flaps or skin graft reconstructions. A total of 51 patients who underwent MMS according to the described technique February 2020-May 2021 were included. The mean age was 76.5 (range 63-94) years and 55% were male. More than half of the lesions were on the nose. Mean lesion sizes were 14.25-55 mm depending on location. Most cases required two surgeries and only one needed a third surgery. Postsurgical defects were repaired using primary closure in 90% of cases. Mean follow-up was 31 months (range 6-48) with no evidence of local recurrence. In conclusion, this approach of serial excisions with MMS can be performed safely and achieve better cosmetic outcomes for patients presenting with large skin tumors of the face or other functionally important areas.